#United States #New York #Pomerantz LLP #Valneva SE #IXCHIQ

Investor Alert: Investigation of Valneva SE by Pomerantz Law Firm

In a critical move, Pomerantz LLP has launched an investigation on behalf of investors in Valneva SE, a biotechnology firm listed on NASDAQ under the ticker symbol VALN. The inquiry follows alarming safety issues related to Valneva’s chikungunya virus vaccine, known as IXCHIQ.

This investigation is particularly timely as it poses potential questions regarding whether Valneva along with specific executives have engaged in any unlawful business practices or securities fraud. Investors who feel affected are encouraged to reach out to Pomerantz to discuss their situation further.

Background of the Situation

The investigation was prompted by a notification from the Centers for Disease Control and Prevention (CDC) on February 25, 2025, which revealed that five hospitalizations involving cardiac or neurological events had occurred following vaccination with IXCHIQ among individuals aged 65 and older. This announcement not only raised public health alarms but also adversely affected the market performance of Valneva’s stocks.

Post-announcement, Valneva’s American Depository Receipt (ADR) suffered a significant drop of $1.06, which equates to a 13.57% decline over the subsequent four trading sessions. The company's ADR closed at $6.75 on February 28, 2025. This decline underlines the investor sentiment and market volatility triggered by the CDC’s warning.

Further exacerbating the situation, on August 22, 2025, the Food and Drug Administration (FDA) announced the suspension of the marketing application for IXCHIQ due to ongoing safety concerns. In the wake of this news, Valneva’s ADR fell by $2.21, translating into an 18.99% decrease and closing at $9.43 on August 25, 2025. These developments have undoubtedly shaken investor confidence and raised eyebrows about corporate governance and accountability within the company.

Pomerantz Law Firm's Commitment

With an established reputation in corporate, securities, and antitrust class action litigations, Pomerantz LLP is well-suited to handle the complexities of this case. Founded by Abraham L. Pomerantz—the class action bar's pioneer—the firm aims to advocate for the rights of investors against potential securities fraud and corporate misconduct.

Pomerantz has a long track record of securing substantial damages for class members, and this instance appears no different as they undertake the challenge of representing affected Valneva investors. Those interested in joining the potential class action are encouraged to connect with Danielle Peyton from the Pomerantz team via the provided contact details.

Implications for Investors

This investigation serves as a significant reminder regarding the volatility and risks associated with investments in biotech companies, particularly those involved in vaccine development. As safety announcements evolve and regulatory scrutiny intensifies, investors must remain vigilant and informed about their holdings. The unfolding of this investigation will be critical in determining the magnitude of Valneva's liability and its impact on the investment landscape. Investors are advised to keep abreast of further developments and consider taking appropriate action to safeguard their interests.

In conclusion, the alert raised by Pomerantz LLP sheds light on essential concerns surrounding Valneva’s business practices and the implications of safety disclosures on investor equity. As this situation develops, stakeholders will be keenly monitoring the outcomes of the investigation and any resultant market shifts.

For additional inquiries regarding this matter, investors can reach out to Danielle Peyton at Pomerantz LLP, with the firm committed to fighting for justice on behalf of those adversely affected by these developments.